Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bremelanotide Phase 2 Dose-Finding in FSAD/HSDD
NCT01382719Phase 2Completed
- Sponsor
- Palatin Technologies, Inc.
- Start
- Jun 2011
- Primary completion
- Sep 2012
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of bremelanotide in Sexual Arousal Disorder and hypoactive sexual desire disorder (HSDD) (4 arms), sponsored by Palatin Technologies, Inc. Primary endpoint: Change From Baseline to End of Study in the Number of Satisfying Sexual Events at 12 weeks. Started Jun 2011; status: completed.
02
Drugs
bremelanotide
03
Conditions
Sexual Arousal Disorderhypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT01382719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01382719.